{"analyses":[{"ciLowerLimit":"0.418","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.894","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0111","paramType":"Hazard Ratio (HR)","paramValue":"0.611","statisticalMethod":"Log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.13","upperLimit":"19.78","value":"14.9"},{"groupId":"OG001","lowerLimit":"8.34","upperLimit":"12.98","value":"9.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomised participants received orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG000","title":"Olaparib 300 mg Twice Daily (bd)"},{"description":"Randomised participants received placebo tablets orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intention to treat (ITT): All randomised patients, Myriad confirmed Breast cancer susceptibility gene mutation (gBRCAm) subgroup.","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Time From Randomisation to Second Subsequent Therapy or Death (TSST)","type":"SECONDARY","unitOfMeasure":"Months"}